Skandinaviska Enskilda Banken (SEB)’s Madrigal Pharmaceuticals MDGL Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,450	Closed	-$7.84M	–	490
2025 Q4	$7.84M	Sell	13,450 -4,913	-27%	-$2.51M	0.03%	327
2025 Q3	$8.44M	Buy	18,363 +14,385	+362%	+$5.37M	0.03%	315
2025 Q2	$1.2M	Hold	3,978	–	–	0.01%	633
2025 Q1	$1.32M	Sell	3,978 -3,820	-49%	-$1.26M	0.01%	616
2024 Q4	$2.43M	Sell	7,798 -1,157	-13%	-$325K	0.01%	539
2024 Q3	$1.9M	Sell	8,955 -26,157	-74%	-$6.69M	0.01%	597
2024 Q2	$9.81M	Hold	35,112	–	–	0.05%	259
2024 Q1	$9.38M	Buy	35,112 +29,840	+566%	+$7.03M	0.05%	282
2023 Q4	$1.22M	Hold	5,272	–	–	0.01%	668
2023 Q3	$770K	Hold	5,272	–	–	0.01%	716
2023 Q2	$1.22M	Buy	+5,272	New	+$1.43M	0.01%	668
2021 Q4	–	Sell	-17,800	Closed	-$1.42M	–	1044
2021 Q3	$1.42M	Buy	+17,800	New	+$1.54M	0.01%	729

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s MDGL Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 13,450 shares — an estimated $7.84M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in MDGL in Q3 2021 and held it in 12 quarters. The position peaked at $9.81M in Q2 2024. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 13,450 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $7.84M.
Skandinaviska Enskilda Banken (SEB) first reported a position in Madrigal Pharmaceuticals in Q3 2021 and held it in 12 quarters.
Skandinaviska Enskilda Banken (SEB)'s Madrigal Pharmaceuticals position peaked at $9.81M in Q2 2024.
380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.